Back to News
Market Impact: 0.35
Boehringer, Sino Enter Cancer Drug Deal Worth Over $7 Billion
Source: Bloomberg
Healthcare & BiotechM&A & Restructuring
Boehringer Ingelheim signed a licensing deal with China’s Sino Biopharmaceutical and its subsidiaries for experimental cancer treatments, potentially worth more than $7 billion. The article does not specify payment terms or clinical milestones.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
More News
- NextDC shares surge 43% after Goodman, Digital Realty stake purchases
- China Blocks SoftBank Acquisition of ABB Robot Unit, FT Says
- Softbank’s $5.4 bln takeover of ABB robotics unit blocked by China- FT
- Host Hotels & Resorts CEO on 3Q Quarterly Results
- Australia’s 188-year-old retailer David Jones enters administration, faces sale
- NextDC shares surge 43% as Goodman, Digital Realty buy stake